CRIS Current Research Information System

DALL'OLIO, FILIPPO GUSTAVO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.666
EU - Europa 1.475
AS - Asia 1.472
AF - Africa 141
SA - Sud America 82
OC - Oceania 5
Totale 4.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.640
IT - Italia 532
SG - Singapore 463
VN - Vietnam 380
CN - Cina 351
DE - Germania 182
SE - Svezia 178
GB - Regno Unito 160
HK - Hong Kong 100
NL - Olanda 95
IN - India 83
BR - Brasile 63
RU - Federazione Russa 54
IE - Irlanda 53
FR - Francia 45
TG - Togo 43
CH - Svizzera 42
KR - Corea 39
FI - Finlandia 38
SC - Seychelles 29
CI - Costa d'Avorio 27
AT - Austria 22
ZA - Sudafrica 19
JO - Giordania 18
BG - Bulgaria 16
NG - Nigeria 16
CA - Canada 15
UA - Ucraina 13
ES - Italia 10
EE - Estonia 9
JP - Giappone 9
BE - Belgio 8
ID - Indonesia 8
PL - Polonia 8
EC - Ecuador 6
AR - Argentina 5
EG - Egitto 5
MX - Messico 5
NI - Nicaragua 4
TR - Turchia 4
AU - Australia 3
BD - Bangladesh 3
PY - Paraguay 3
RO - Romania 3
CO - Colombia 2
IQ - Iraq 2
IR - Iran 2
PE - Perù 2
PS - Palestinian Territory 2
PT - Portogallo 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KI - Kiribati 1
LB - Libano 1
LT - Lituania 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 4.841
Salva come PNG Salva come JPEG
Città #
Singapore 321
Ashburn 215
Chandler 184
Dong Ket 140
Fairfield 138
Southend 135
Hefei 99
Hong Kong 99
Santa Clara 94
Bologna 89
Seattle 76
Woodbridge 67
Houston 62
Beijing 60
Wilmington 57
Dublin 53
Princeton 51
Rome 49
Dallas 48
Hanoi 48
Lomé 43
Cambridge 41
Ho Chi Minh City 40
Seoul 37
Boardman 36
Bern 35
Los Angeles 33
Milan 32
Helsinki 28
Abidjan 27
New York 26
Turin 22
Ann Arbor 19
Amman 18
Munich 18
Abeokuta 16
Berlin 16
Bremen 16
Sofia 16
Westminster 15
Buffalo 14
Florence 14
Vienna 14
Frankfurt am Main 13
Redondo Beach 13
San Diego 13
Redmond 12
Des Moines 11
Nuremberg 11
São Paulo 11
Nanjing 10
Bengaluru 9
Jinan 9
Ravenna 9
Brussels 8
Chicago 8
Da Nang 8
Montreal 8
Turku 8
Falkenstein 7
Moncalieri 7
Stockholm 7
Tokyo 7
Changsha 6
Guangzhou 6
Manchester 6
Phoenix 6
Redwood City 6
Torino 6
Visakhapatnam 6
Biên Hòa 5
Boston 5
Brescia 5
Bühl 5
Bắc Giang 5
Haiphong 5
London 5
Olalla 5
Orem 5
Padova 5
Pune 5
Rio de Janeiro 5
San Jose 5
Shanghai 5
Shenyang 5
Warsaw 5
Bari 4
Brooklyn 4
Hyderabad 4
Kuban 4
Lauterbourg 4
Managua 4
Moscow 4
Norwalk 4
Palermo 4
Paris 4
Salt Lake City 4
San Francisco 4
Seville 4
Tongling 4
Totale 3.028
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 401
The 'surprise' question in advanced cancer patients: A prospective study among general practitioners. 241
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC 240
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience 239
Adjuvant chemotherapy for resected colorectal cancer metastases: literature revision and meta-analysis 231
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 230
CLINICOPATHOLOGICAL, MOLECULAR AND ONCOLOGICAL FEATURES OF SPORADIC EARLY ONSET COLORECTAL CANCERS 220
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 180
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 180
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 179
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 174
Clinical significance of ROS1 5’ deletions in non-small cell lung cancer 157
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 147
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter 146
Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role? 137
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study 128
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors 126
Clinical and demographic factors associated to the place of death in advanced cancer patients assisted at home in Italy 123
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non–Small Cell Lung Adenocarcinoma 122
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 116
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 113
Expected and non-expected immune-related adverse events detectable by CT 112
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 107
Cardiac Toxicity From Afatinib in EGFR-Mutated NSCLC: A Rare But Possible Side Effect 106
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 104
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 103
Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series 101
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 100
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 89
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab. 89
Role of PD-L1 assessment in advanced NSCLC: does it still matter? 66
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 55
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 49
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 41
Totale 4.952
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.705
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.705
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021386 0 0 0 0 0 40 8 23 41 27 10 237
2021/2022591 45 13 24 33 54 18 21 57 38 44 164 80
2022/2023839 60 148 53 99 65 63 26 53 127 18 57 70
2023/2024289 35 35 15 30 21 51 4 26 14 13 21 24
2024/20251.002 70 113 73 54 127 42 54 69 42 108 73 177
2025/20261.198 257 272 177 146 224 122 0 0 0 0 0 0
Totale 4.952